Hu Xue, Chen Jing
Department of Occupation Medicine, Hangzhou Hospital for the Prevention and Treatment of Occupational Diseases, China.
J Renin Angiotensin Aldosterone Syst. 2019 Jan-Mar;20(1):1470320319827207. doi: 10.1177/1470320319827207.
: The association between angiotensin II type 1 receptor ( AGTR1) gene A1166C polymorphism and cancer risk has been investigated in many studies. However, the results have been inconclusive. A meta-analysis was performed to obtain a more precise estimation of the relationship.
: The PubMed and China National Knowledge Infrastructure databases were searched for published literature. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strengths of association.
: Ten studies, including 1553 patients and 1904 controls, were included in the meta-analysis. Overall, there were no significant associations between the AGTR1 gene A1166C polymorphism and cancer risk in the general population (CC vs AA: OR = 1.09, 95% CI = 0.50-2.37; AC vs AA: OR = 1.54, 95% CI = 0.81-2.91; dominant model: OR = 1.46, 95% CI = 0.77-2.79; recessive model: OR = 1.12, 95% CI = 0.84-1.49). In a subgroup analysis by nationality and cancer type, the results also showed no association between this polymorphism and cancer risk.
: This meta-analysis demonstrated that the AGTR1 gene A1166C polymorphism does not appear to be related to the risk of cancer.
多项研究探讨了血管紧张素II 1型受体（AGTR1）基因A1166C多态性与癌症风险之间的关联。然而，结果尚无定论。进行一项荟萃分析以更精确地估计二者关系。
检索PubMed和中国知网数据库中的已发表文献。采用比值比（OR）及95%置信区间（CI）评估关联强度。
荟萃分析纳入10项研究，共1553例患者和1904例对照。总体而言，在普通人群中，AGTR1基因A1166C多态性与癌症风险无显著关联（CC与AA比较：OR = 1.09，95%CI = 0.50 - 2.37；AC与AA比较：OR = 1.54，95%CI = 0.81 - 2.91；显性模型：OR = 1.46，95%CI = 0.77 - 2.79；隐性模型：OR = 1.12，95%CI = 0.84 - 1.49）。按国籍和癌症类型进行亚组分析，结果也显示该多态性与癌症风险无关联。
这项荟萃分析表明，AGTR1基因A1166C多态性似乎与癌症风险无关。
